Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity.
Ontology highlight
ABSTRACT: The promise of 'personalized cancer care' with therapies toward specific molecular aberrations has potential to improve outcomes. However, there is recognized heterogeneity within any given tumor-type from patient to patient (inter-patient heterogeneity), and within an individual (intra-patient heterogeneity) as demonstrated by molecular evolution through space (primary tumor to metastasis) and time (after therapy). These issues have become hurdles to advancing cancer treatment outcomes with novel molecularly targeted agents. Classic trial design paradigms are challenged by heterogeneity, as they are unable to test targeted therapeutics against low frequency genomic 'oncogenic driver' aberrations with adequate power. Usual accrual difficulties to clinical trials are exacerbated by low freq
SUBMITTER: Catenacci DV
PROVIDER: S-EPMC4402102 | biostudies-literature | 2015 May
REPOSITORIES: biostudies-literature
ACCESS DATA